This piece delivers a rare, unvarnished victory lap for oncology, arguing that the decades-long siege on pancreatic cancer has finally been breached not by immunotherapy, but by a fundamental rethinking of how drugs bind to proteins. While the media often fixates on the latest celebrity diagnosis, Works in Progress cuts through the noise to explain why a specific molecular mechanism—previously dismissed as impossible—is now doubling survival rates for a disease that was once a guaranteed death sentence.
The Silent Killer and the False Promise of Immunotherapy
The article opens with a stark reality check: for most of the last half-century, a diagnosis of metastatic pancreatic cancer was a death sentence. It uses the high-profile case of former Senator Ben Sasse to illustrate the stakes, noting that while his 76 percent tumor reduction was described as a 'miracle,' the treatment came with a severe skin rash that 'told a more complicated story.' This grounding in physical reality is crucial; it prevents the narrative from becoming pure hype.
The piece effectively dismantles the assumption that the recent revolution in cancer care applies to everyone. It explains that while immunotherapies have redrawn boundaries for melanoma, 'metastatic pancreatic cancer is particularly good at protecting itself against immune attack.' The editors note that pancreatic tumors build a 'dense, scar-like layer of tissue that physically blocks a patient’s immune cells from entering the tumor.' This is a vital distinction. Unlike melanoma, which is 'genetically noisy' and full of mutations that flag it for immune destruction, pancreatic tumors are 'comparatively quiet' and remain hidden.
'Pancreatic cancer has the highest mortality rate of all major cancers.'
The argument here is that we cannot rely on the body's natural defenses for this specific enemy. The tumor creates a hostile environment by attracting suppressive cells and releasing molecules that dampen immune function. This framing is essential because it explains why the 'precision medicine' promise of the early 2000s failed to deliver a cure. The piece reminds us that after the Human Genome Project concluded in 2003, the optimism was 'intoxicating,' yet progress has been 'mediocre' because many cancer-driving proteins are simply 'beyond reach' for conventional drugs.
Cracking the 'Undruggable' Target
The core of the article's technical insight lies in its explanation of why RAS, a protein mutated in roughly a quarter of all human cancers, was labeled 'undruggable' for so long. The piece argues that the problem was 'fundamental geometry': RAS has a 'smooth and chemically inhospitable' surface with no clear binding sites for drugs to latch onto.
For years, drug designers were stuck trying to find a 'ready-made pocket' in the protein. The article highlights a breakthrough in 2013 where researchers found a way to target a specific mutant version, G12C, but notes this was a dead end for pancreatic cancer, where that mutation is rare. The real game-changer, as the editors detail, is the rise of 'molecular glues.'
'Molecular glues take a different approach from most small molecule drugs. Rather than binding a pocket, they create new connections between proteins.'
This is the piece's most significant contribution to the public understanding of drug discovery. Instead of jamming a key into a lock, these drugs act as a chemical intermediary, forcing two proteins to stick together. The article traces this back to the late 1990s with thalidomide, a drug 'infamous for causing birth defects' that was later repurposed to work as a molecular glue for multiple myeloma. This historical context adds necessary depth, showing that the science was brewing long before it was applied to RAS.
The breakthrough for pancreatic cancer came when scientists realized a common protein, Cyclophilin A, could serve as a bridging partner. Using advances in cryo-electron microscopy, they mapped the interface and designed daraxonrasib. The result? 'Roughly twice as long' survival for patients compared to standard chemotherapy. This is not a cure, but for a disease where median survival is measured in months, the editors argue it represents a 'genuine turning point.'
The Limits of Victory and the Path Forward
However, the piece refuses to succumb to triumphalism. It immediately pivots to the limits of targeted therapy, noting that 'resistance inevitably emerges.' The article details how tumors adapt, with some acquiring mutations that physically prevent the molecular glue from forming its complex, while others simply amplify copies of the target protein.
'Because resistance to any single agent is essentially guaranteed, the future lies in combinations: hitting multiple vulnerabilities simultaneously, or switching strategies as the tumor evolves.'
This is a sobering but necessary counterpoint. The article suggests that our current regulatory framework, built for long, linear trials, is ill-equipped for the rapid, adaptive testing required to stay ahead of evolving tumors. It calls for making small-scale trials easier to conduct, a policy shift that is often overlooked in favor of celebrating new drug approvals.
Critics might note that while doubling survival is a massive leap, the side effects and the eventual emergence of resistance mean that 'undruggable' may just be a temporary label rather than a permanent defeat. The piece acknowledges this by citing the parallel success against PI3Kα in breast cancer, reinforcing the broader lesson that 'the assumption that certain targets are simply beyond reach has repeatedly turned out to be wrong.'
'The broader lesson of this era, though, is one of optimism.'
Bottom Line
Works in Progress succeeds by shifting the narrative from the tragedy of pancreatic cancer to the mechanics of a hard-won scientific breakthrough, grounding high-level biochemistry in the tangible reality of extended life. Its greatest strength is the clear explanation of molecular glues as a paradigm shift, while its only vulnerability is the inherent uncertainty of how long these gains will last against a rapidly adapting enemy. Readers should watch for how quickly combination therapies can be tested, as that will determine whether this 'turning point' becomes a new standard of care or a fleeting victory.